Last updated on April 2017

A Long-term Access Programme for Subjects With Severe Asthma


Brief description of study

This is a Long-term Access Programme (LAP) which aims to support provision of mepolizumab, until it is commercially available, to eligible subjects with severe asthma who participated in a GSK-sponsored mepolizumab clinical study 200862 and 200363. Eligible subjects will initiate mepolizumab within a 6-month period following the individual subject's last scheduled visit in their preceding clinical study. For each subject benefit versus risk will be assessed throughout the study to support continued treatment with mepolizumab.

Clinical Study Identifier: NCT02543112

Find a site near you

Start Over

GSK Investigational Site

Rolling Hills Estates, CA United States
  Connect »

GSK Investigational Site

Baltimore, MD United States
  Connect »

GSK Investigational Site

Mar del Plata, Argentina
  Connect »

GSK Investigational Site

Buenos Aires, Argentina
  Connect »

GSK Investigational Site

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »

GSK Investigational Site

St-Charles-Borromée, QC Canada
  Connect »

GSK Investigational Site

Hradec Kralove, Czech Republic
  Connect »

GSK Investigational Site

Kralupy nad Vltavou, Czech Republic
  Connect »

GSK Investigational Site

Olomouc, Czech Republic
  Connect »

GSK Investigational Site

Marseille Cedex 20, France
  Connect »

GSK Investigational Site

Montpellier cedex 5, France
  Connect »

GSK Investigational Site

Haidari / Athens, Greece
  Connect »

GSK Investigational Site

Leeuwarden, Netherlands
  Connect »

GSK Investigational Site

San Martin de Porres, Peru
  Connect »

GSK Investigational Site

Ekaterinburg, Russian Federation
  Connect »

GSK Investigational Site

Irkutsk, Russian Federation
  Connect »

GSK Investigational Site

Moscow, Russian Federation
  Connect »

GSK Investigational Site

Novosibirsk, Russian Federation
  Connect »

GSK Investigational Site

Saint Petesburg, Russian Federation
  Connect »

GSK Investigational Site

St'Petersburg, Russian Federation
  Connect »

GSK Investigational Site

St. Petersburg, Russian Federation
  Connect »

GSK Investigational Site

Stavropol, Russian Federation
  Connect »

GSK Investigational Site

Voronezh, Russian Federation
  Connect »

GSK Investigational Site

Spisska Nova Ves, Slovakia
  Connect »

GSK Investigational Site

Alcorcón (Madrid), Spain
  Connect »

GSK Investigational Site

Pozuelo de Alarcón/Madrid, Spain
  Connect »

GSK Investigational Site

Santiago de Compostela. La Coruña., Spain
  Connect »

GSK Investigational Site

Dnipropetrovsk, Ukraine
  Connect »

GSK Investigational Site

Bradford, United Kingdom
  Connect »

GSK Investigational Site

Plymouth, United Kingdom
  Connect »

GSK Investigational Site

Swansea, United Kingdom
  Connect »